Major Update: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points

Updated review (total 5 RCTs; n=7767) found 10-day course of remdesivir probably results in little to no mortality reduction (risk ratio 0.93; 95% CI 0.82 to 1.06) but may result in a small reduction in proportion of patients receiving mechanical ventilation (0.71; 0.56-0.90]).

SPS commentary:

The results of the updated analysis also found remdesivir probably results in a moderate increase in the percentage of patients who recovered (ARD 6.5% [95% CI 2.4% to 10.7%]), and reduces serious adverse events (ARD −6.3% [−10.2% to −2.4%]).

 

This update included final results from ACTT-1 study (preliminary results only previously available) and interim published results from a new RCT (Solidarity).

 

The Scientific Medical Policy Committee of the American College of Physicians (ACP) is maintaining rapid, living practice points on the use of remdesivir as a treatment for COVID-19. The second version, based on this review, is now available. 

Annals of Internal Medicine

Resource links:

ACP clinical guidelines